

Efficacy and tolerability of ALLERGIKA®-Eyelid Cream MED in test subjects with damaged skin barrier

(Wohlrab et al., JDDG, 1616-0379, 2015)



Study center	Institute for Applied Dermatopharmacy Martin-Luther-Universität Halle-Wittenberg
Head of Study	Prof. Dr. Johannes Wohlrab
Objective	Validation of the influence of ALLERGIKA®-Eyelid Cream MED on the barrier function using standardized function-impaired skin (stripping) compared to normal skin.
Target parameters	1. Transepidermal water loss (TEWL) 2. Water content in the horny layer of the stratum corneum (SC) 3. Fluorescence images of the hydrophilic and lipophilic phase
Implementation	1. Tewametry at 0d, 3d, 7d and 28d 2. Corneometry at 0d, 3d, 7d and 28d 3. Fluorescence analysis of the hydrophilic and lipophilic phase in intact and damaged skin (performed by Richter et al., Charité Berlin)
Study product	ALLERGIKA®-Eyelid Cream MED
Study design	Prospective, monocentric, randomized study with intraindividual comparison
Participants	27 healthy male and female
Study period	4 weeks
Application area	Inner forearms (application twice daily)

Results

1. ALLERGIKA®-Eyelid Cream MED was very well tolerated by all test subjects
2. The artificially caused barrier damage was compensated, the skin normalised completely (Fig. 1)
3. The fluorescence images (Fig. 2) of the lipophilic (red) and hydrophilic phase (green) confirm the efficacy of the formulation
4. The lipophilic galenic (W/O) demonstrates a long-lasting protective effect, especially on damaged skin (Fig. 2, lipophilic phase)




Fig. 1: Decrease in TEWL with stripped skin




Fig. 2: Fluorescence images of the hydrophilic (green) and lipophilic phase (red) in intact and damaged skin

Conclusion

The study demonstrates a clear repair effect on damaged barrier function due to the lipophilic galenic. ALLERGIKA®-Eyelid Cream MED is therefore particularly

suitable for dry, subacute-chronic eyelid eczema, especially in cases of atopic, contact-allergic and irritative eyelid eczema.



Source: Used with kind permission of Prof. Dr. med. A. Enk

Efficacy of ALLERGIKA®-Eyelid Cream MED on patients with reddened, dry, flaky eyelid eczema

(Dermatológia pre prax, 2018;12(3):119-124, ISSN: 1337-1746.)




Study center	Clinic of Dermatovenerology at the University Hospital in Bratislava, Faculty of Medicine, Comenius University in Bratislava, Slovakia
Head of Study	Dr. med. Milica Malíčková
Objective	Assessing the efficacy and tolerability of lipophilic ALLERGIKA®-Eyelid Cream MED in dry flaky eyelid eczema
Target parameters	1. Symptoms: Redness, dryness, scaling 2. Score: Investigator Global Assessment (IGA), Patient Global Assessment (PGA)
Implementation	1. Doctor and patient assess the symptoms of redness, dryness of the skin and the presence of scales in the eyelid area 2. Determination of the IGA and PGA score at 0d, 7d and 21d 3. Assessment of patient satisfaction with the monitored product in relation to the product characteristics
Study product	ALLERGIKA®-Eyelid Cream MED
Study design	Prospective, multicenter, non-randomized study
Participants	22 male and female patients with atopic dermatitis (50%), allergic contact dermatitis (41%) and irritative contact dermatitis (9%)
Study period	3 weeks
Application area	Upper and lower eyelid

Results

1. 50% reduction of eczema symptoms redness, skin dryness and scaling already after 7 days.
2. Sustained significant reduction of symptoms by 75% after 21 days
3. The consistency, tolerability and application of ALLERGIKA®-Eyelid Cream MED was assessed as very good.

IGA assessment: assessment by the dermatologists



Conclusion

In this clinical study in patients with eyelid eczema, there was a rapid improvement of 75% in the main symptoms such as redness, scaling and skin dryness with very good acceptance.

ALLERGIKA®-Eyelid Cream MED is suitable for the treatment of atopic, contact-allergic and irritative eyelid eczema.



Source: Used with kind permission of Prof. Dr. J. Ring